(Q34700658)

4 August 2017

1 reference

title

Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice (English)

1 reference

4 August 2017

4

Robert S Negrin

1 reference

4 August 2017

Michael R Verneris

1

1 reference

4 August 2017

Jeanette Baker

series ordinal

2

1 reference

4 August 2017

Matthias Edinger

series ordinal

3

1 reference

4 August 2017

1 May 2002

1 reference

Journal of Clinical Immunology

4 August 2017

1 reference

4 August 2017

22

1 reference

4 August 2017

3

1 reference

4 August 2017

131-136

1 reference

https://scigraph.springernature.com/pub.10.1023/a:1015415928521

4 August 2017

0 references

cites work

Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.

1 reference

12 December 2020

Memory CD8 T lymphocytes express inhibitory MHC-specific Ly49 receptors

1 reference

12 December 2020

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation

1 reference

12 December 2020

Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma

1 reference

12 December 2020

Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells.

1 reference

12 December 2020

Regression of extensive pulmonary metastases in mice by adoptive transfer of antigen-specific CD8(+) CTL reactive against tumor cells expressing a naturally occurring rejection epitope

1 reference

12 December 2020

Resistance of ex vivo expanded CD3+CD56+ T cells to Fas-mediated apoptosis.

1 reference

12 December 2020

Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation

1 reference

12 December 2020

Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells

1 reference

12 December 2020

Induction of CD4+ T cell alloantigen-specific hyporesponsiveness by IL-10 and TGF-beta

1 reference

12 December 2020

Heterogeneity of NK1.1+ T cells in the bone marrow: divergence from the thymus

1 reference

12 December 2020

Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice

1 reference

12 December 2020

Tissue-specific segregation of CD1d-dependent and CD1d-independent NK T cells

1 reference

12 December 2020

The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand

1 reference

12 December 2020

Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12.

1 reference

12 December 2020

Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity

1 reference

12 December 2020

Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages.

1 reference

12 December 2020

Recognition of the class Ib molecule Qa-1(b) by putative activating receptors CD94/NKG2C and CD94/NKG2E on mouse natural killer cells

1 reference

12 December 2020

The Fas counterattack: a molecular mechanism of tumor immune privilege

1 reference

12 December 2020

Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells

1 reference

12 December 2020

Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation

1 reference

12 December 2020

Differential expression of CD8α and CD8β associated with MHC-restricted and non-MHC-restricted cytolytic effector cells

1 reference

12 December 2020

CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides

1 reference

12 December 2020

Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.

1 reference

12 December 2020

Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity

1 reference

12 December 2020

A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma

1 reference

12 December 2020

Mouse CD1-specific NK1 T cells: development, specificity, and function

1 reference

12 December 2020

1 reference

12 December 2020

Fas and FasL in the homeostatic regulation of immune responses

1 reference

12 December 2020

A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.

1 reference

12 December 2020

Donor-type activated natural killer cells promote marrow engraftment and B cell development during allogeneic bone marrow transplantation

1 reference

12 December 2020

Donor leukocyte infusions in acute lymphocytic leukemia

1 reference

12 December 2020

Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients

1 reference

12 December 2020

Turning on natural killer cells

1 reference

12 December 2020

Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis.

1 reference

12 December 2020

Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production

1 reference

12 December 2020

Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor

1 reference

12 December 2020

Human NK-cell receptors

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1015415928521

1 reference

Dimensions Publication ID

4 August 2017

0 references

1 reference